The global Digital Biomarkers Market size is expected to reach USD 13.97 billion by 2030, growing at a CAGR of 22.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising adoption of mobile applications & devices related to healthcare, and rising awareness regarding the wide therapeutic applications, increased utilization of smartphones, and the introduction of novel wearable technologies. According to Accenture Health and Life Sciences Experience Survey in 2021, 26% of the people living in the U.S. experienced enhanced access to healthcare services with the adoption of healthcare applications and devices.
Further, governmental organizations have expressed
interest in creating digital biomarker-based medication due to the significant
hardship brought on by the Covid-19 outbreak. For instance, in March 2022,
AstraZeneca teamed up with UK-based medical technology company Huma
Therapeutics to develop Software as a Medical Device (SaMD) companion
applications for a range of therapeutic diseases. These applications combined
predictive algorithms, digital biomarkers, and real-world data.
The rising cost of drug research, combined with its
low relative success rate, is fuelling rapid creation of digital biomarkers
(DBMs). DBMs in this field assist in focusing on particular decentralized
clinical study areas, including early-onset Alzheimer's or dementia, thereby
lowering the time, failure rate of drug development, and cost. According to a
blog post by a digital solutions company called healthxl, the Digital Medicine
Society (DiME) lately brought together top pharmaceutical companies, including
Eli Lilly, Merck, and Biogen, to ascertain a set of core standard digital endpoints
for dementia and Alzheimer's disease. This was done to solve the issue of
assessing the efficacy of new therapies in human subjects as well as to reduce
time & money spent on research and development of new remedies.
Regional governments across the globe are supporting
the adoption of biomarkers by conducting awareness programs and investing in
the development of digital
health. According to an article published by the UC Davis
School of Medicine in 2022, the Digital Health Equity Program conducted by
UC Davis Health received funding of USD 1.7 million from the federal
government. This government funding is expected to contribute to the development
of a regional digital public health platform capable of enhancing access to
healthcare facilities for vulnerable populations in Northern California and
Sacramento.
Emerging players, such as AliveCor Inc, Empatica,
Inc., Huma, and VivoSense, are adopting strategies such as acquisitions,
collaborations, partnerships, and new product launches is anticipated to drive
the market growth over the forecast period. For instance, in January
2023, Huma, a digital health company, announced the acquisition of Alcedis
to expand its capabilities in the digital clinical trial space. The goal of
this acquisition is to develop healthcare solutions across various stages of
development processes.
Request For Free Sample Report @ Digital Biomarkers Market Report
List of Key Players in the Digital Biomarkers Market
- ActiGraph LLC
- AliveCor Inc.
- Koneksa
- Altoida Inc.
- Amgen Inc.
- Biogen Inc.
- Empatica Inc.
- Vivo Sense
- IXICO plc
- Adherium Limited
- Neurotrack Technologies, Inc.
- Aural Analytic
- Huma
- Sonde Health, Inc
Digital Biomarkers Market Report Highlights
- Based on type, wearables held the largest market share of 39.5% in
2023, owing to the emergence of new wearables for healthcare purposes. It
is anticipated that the market demand for new wearable devices is expected
to increase because of government authorities approving new wearable
devices
- Based on clinical practice, the diagnosis digital biomarkers held
the largest market share of 32.4% in 2023. Diagnosis digital biomarkers
are quantifiable indicators of health conditions or diseases, derived from
digital technologies such as wearables, mobile apps, and medical devices.
They enable early detection, accurate diagnosis, and personalized
treatment by analyzing physiological, behavioral, biochemical, imaging,
and patient-reported data. These innovative tools contribute to the
advancement of healthcare by improving patient outcomes and facilitating
remote monitoring and disease management
- Based on therapeutic area, the cardiovascular disease segment
dominated the market with a share of 19.8% in 2023, owing to the growing
number of therapeutic applications and increasing incidences of
cardiovascular disorders globally
- Based on end use, the healthcare companies held the largest market
share of 50.1% in 2023, owing to the fact that healthcare companies have
been working toward integrating digital measurements across the spectrum
of clinical care & research
- North America dominated the market and accounted for a revenue share
of 58.4% in 2023, owing to the strong presence of leading market players,
significant product launches, and an increase in investments in the
R&D biomarkers
Digital Biomarker
Market Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2024 |
USD 4.09
billion |
|
Revenue
forecast in 2030 |
USD 13.97
billion |
|
Growth
rate |
CAGR of
22.7% from 2024 to 2030 |
|
Actual
data |
2018 -
2023 |
|
Forecast data |
2024 - 2030 |
Related Press Release@ Digital Biomarkers Market Report
Digital Biomarkers Market Segmentation
Grand View Research has segmented the global digital
biomarkers market based on type, clinical practice, therapeutic area, end-use,
and region:
Digital Biomarkers Type Outlook (Revenue, Million,
2018 - 2030)
- Wearable
- Mobile Based Applications
- Sensors
- Others
Digital Biomarkers Clinical Practice Outlook
(Revenue, Million, 2018 - 2030)
- Diagnostic Digital Biomarkers
- Monitoring Digital Biomarkers
- Predictive And Prognostic Digital Biomarkers
- Other's (Safety, Pharmaco dynamics/ Response, Susceptibility)
Digital Biomarkers Therapeutic Area Outlook
(Revenue, Million, 2018 - 2030)
- Cardiovascular And Metabolic Disorders (CVMD)
- Respiratory Disorders
- Psychiatric Disorders
- Sleep & Movement Disease
- Neurological Disorders
- Musculoskeletal Disorders
- Others (Diabetes, Pain Management)
Digital Biomarkers End-use Outlook (Revenue,
Million, 2018 - 2030)
- Healthcare Companies
- Healthcare Providers
- Payers
- Others (Patient, Caregivers)
Digital Biomarkers Regional Outlook (Revenue,
Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- Spain
- Italy
- France
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Explore Horizon, the world's most expansive market
research database
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
